Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Rance, E ^a   Tanner, J E ^a   Alfieri, C ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

fibrosis; interferon ; interleukin 8; NF B inhibitor; reticuloendotheliosis

Indexed keywords

6 AMINO 4 (PHENOXYPHENENYLETHYLAMINO)QUINAZOLINE; BETA ACTIN; CD81 ANTIGEN; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; QUINAZOLINE DERIVATIVE; THALIDOMIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIRUS RNA; WEDELOLACTONE;

ARTICLE; CELL LINE; CELL METABOLISM; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA REPLICATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

CELL LINE; ENZYME INHIBITORS; HEPACIVIRUS; HEPATOCYTES; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-8; NF-KAPPA B; RNA, VIRAL; THALIDOMIDE; VIRUS REPLICATION;

EID: 84855837034     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01505.x     Document Type: Article

References (42)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 1: 35-47.
2. Mehta G, Rothstein KD,. Health maintenance issues in cirrhosis. Med Clin North Am 2009; 93: 901-915, viii-ix.
3. Spengler U, Nattermann J,. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007; 3: 141-155.
4. Teo SK, Stirling DI, Zeldis JB,. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 2: 107-114. (Pubitemid 40247808)
5. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT,. Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci 2006; 3: 403-418.
6. Yang YY, Lee KC, Huang YT, et al. Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers. Liver Int 2009; 5: 678-685.
7. Caseiro MM,. Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. Rev Inst Med Trop Sao Paulo 2006; 2: 109-112. (Pubitemid 43735878)
8. Milazzo L, Biasin M, Gatti N, et al. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. Am J Gastroenterol 2006; 2: 399-402. (Pubitemid 43381686)
9. Schijman A, Colina R, Mukomolov S, et al. Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes. Clin Diagn Lab Immunol 2004; 2: 433-435. (Pubitemid 38380831)
10. Raufman JP, Lamps LW,. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C. Am J Gastroenterol 2001; 11: 3209-3211. (Pubitemid 33095373)
11. Muriel P,. NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol 2009; 2: 91-100.
12. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr,. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 25: 22382-22387.
13. Boya P, Larrea E, Sola I, et al. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 2001; 5: 1041-1048. (Pubitemid 33032041)
14. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 7: 791-796. (Pubitemid 41021213)
15. Roux P, Alfieri C, Hrimech M, Cohen EA, Tanner JE,. Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J Virol 2000; 10: 4658-4665. (Pubitemid 30237891)
16. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M,. Identification and characterization of an IkappaB kinase. Cell 1997; 2: 373-383.
17. Duckett CS, Perkins ND, Kowalik TF, et al. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol 1993; 3: 1315-1322. (Pubitemid 23068066)
18. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T,. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006; 5: 2334-2339.
19. Tobe M, Isobe Y, Tomizawa H, et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg Med Chem 2003; 3: 383-391. (Pubitemid 36051028)
20. Kobori M, Yang Z, Gong D, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 2004; 1: 123-130. (Pubitemid 38111379)
21. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Hayashi H,. A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives. Bioorg Med Chem 2003; 18: 3869-3878. (Pubitemid 36970113)
22. Takeuchi T, Katsume A, Tanaka T, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999; 3: 636-642. (Pubitemid 29106771)
23. Kohsaka T, Yuan ZR, Guo SX, et al. The significance of human jagged 1 mutations detected in severe cases of extrahepatic biliary atresia. Hepatology 2002; 1: 904-912.
24. Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006; 4: 824-831. (Pubitemid 46335531)
25. Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O,. Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation 2010; 7: 16.
26. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005; 6: 2064-2075. (Pubitemid 41772981)
27. Yagyu T, Kobayashi H, Matsuzaki H, et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 2005; 5: 3017-3021. (Pubitemid 40686358)
28. Tanner JE,. Nucleosomes activate NF-kappaB in endothelial cells for induction of the proangiogenic cytokine IL-8. Int J Cancer 2004; 1: 155-160. (Pubitemid 39249504)
29. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA,. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004; 3: 1448-1455. (Pubitemid 38095855)
30. Gieling RG, Burt AD, Mann DA,. Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin Liver Dis 2008; 4: 915-937, xi.
31. Lim YS, Kim WR,. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 4: 733-746, vii.
32. Moynagh PN,. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 9: 469-476. (Pubitemid 41139256)
33. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S,. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006; 51: 6844-6867. (Pubitemid 44657856)
34. Vallabhapurapu S, Karin M,. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
35. Verma IM, Stevenson JK, Schwarz EM, Van AD, Miyamoto S,. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 22: 2723-2735. (Pubitemid 3009952)
36. Choi SH, Park KJ, Ahn BY, Jung G, Lai MM, Hwang SB,. Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase. Mol Cell Biol 2006; 8: 3048-3059.
37. Wang RP, Zhang M, Li Y, et al. Differential regulation of IKK alpha-mediated activation of IRF3/7 by NIK. Mol Immunol 2008; 7: 1926-1934.
38. Binder M, Kochs G, Bartenschlager R, Lohmann V,. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 2007; 5: 1365-1374. (Pubitemid 350155518)
39. Liao QJ, Ye LB, Timani KA, et al. Hepatitis C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappaB activation. World J Gastroenterol 2005; 41: 6433-6439. (Pubitemid 43136878)
40. Yoshida H, Kato N, Shiratori Y, et al. Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor. J Biol Chem 2001; 19: 16399-16405.
41. Szabo G, Dolganiuc A,. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008; 3: 675-692, x. (Pubitemid 351952475)
42. Wang J, Basagoudanavar SH, Wang X, et al. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J Immunol 2010; 3: 1720-1729.